Researchers from Canada randomly assigned adults with C. diff infections to receive frozen or fresh FMT via enema. Thirteen weeks after treatment, 83.5 percent of the frozen FMT group and 85 percent of the fresh FMT group had clinical resolution of diarrhea without relapse.
“In this clinical trial, the use of frozen FMT compared with fresh FMT for the treatment of recurrent or refractory CDI was noninferior in terms of efficacy; findings for frozen FMT and fresh FMT were similar in terms of safety,” the study authors wrote. “Given the potential advantages of providing frozen FMT, its use is a reasonable option in this setting.”
More articles on C. diff:
Predictive preventive model reduces C. diff cases in ICU: 3 study findings
Research highlights how antibiotics enable C. diff infections
Mayo Clinic reduces C. diff infections 30% using UV light disinfection
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
